Trials / Active Not Recruiting
Active Not RecruitingNCT02273375
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,415 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI4736 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-02-24
- Primary completion
- 2025-07-23
- Completion
- 2026-01-31
- First posted
- 2014-10-24
- Last updated
- 2025-08-12
Locations
271 sites across 19 countries: United States, Australia, Brazil, Bulgaria, Canada, China, France, Hungary, Italy, Japan, Netherlands, New Zealand, Poland, Romania, Singapore, South Korea, Spain, Taiwan, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02273375. Inclusion in this directory is not an endorsement.